Hypolidemic therapy today. New challenges and opportunities of statines
https://doi.org/10.21518/2079-701X-2018-5-48-53
Abstract
Prevention of fatal complications in patients with high cardiovascular risk means achieving target blood cholesterol and its fraction in low-density lipoprotein levels, which level depends on the cardiovascular risk (CVR) degree and is determined by the guidelines of the European Cardiology Society (2016) and the Russian National Atherosclerosis Society (2017). When choosing statins for lipid-lowering therapy, one should be guided by the hepatic metabolism nature, hypolipidemic activity, and the pleiotropic profiles of the drug.
About the Authors
V. P. Mikhin
Kursk State Medical University
Russian Federation
MD, Prof.
Russian Federation
MD, Prof.
V. V. Vorotyntseva
Kursk State Medical University
Russian Federation
Russian Federation
Yu. A. Zhilyaeva
Kursk State Medical University
Russian Federation
PhD in medicine
Russian Federation
PhD in medicine
M. A. Chernyatina
Kursk State Medical University
Russian Federation
Russian Federation
PhD in medicine, Assistant Prof.
N. I. Gromnatsky
Kursk State Medical University
Russian Federation
MD, Prof.
Russian Federation
MD, Prof.
O. A. Sushenya
Kursk State Medical University
Russian Federation
Russian Federation
References
1. Sergienko IV, Ansheles AA, Kukharchuk VV. Atherosclerosis and dyslipidemia: modern aspects of pathogenesis, diagnosis and treatment. PatiSS., 2017, 128 p.
2. Boytsov SA, Kalinina AM, Ipatov PV. Prophylactic medical examination of the adult population as a mechanism for identifying cardiovascular diseases and establishing followup monitoring. Vestnik Roszdravnadzora, 2015, 5: 9-16.
3. Shalnova SA, Vilkov VG, Metelskaya VA, Balanova YuA, Kapustina AV. Thirty-year dynamics of the average characteristics of blood lipids in populations of the Russian Federation and the United States. Ratsionalnaya Farmakoterapiya v Kardiologii, 2018, 14 (1): 4-11. doi: 10.20996 / 1819-6446-2018-14-1-4-11.
4. EOK/EOA guidelines for the diagnosis and management of dyslipidemia. The 2016 working group of the European Cardiology Society (ECS) and the European Atherosclerosis Society (EAS) for the diagnosis and management of dyslipidemia. Ross iyskiy Kardiologicheskiy Zhurnal, 2016, 5 (145): 10-78.
5. Diagnosis and management of lipid metabolism disorders for the prevention and treatment of atherosclerosis. Russian guidelines VI revision, Moscow 2017. https://noatero.ru/sites/default/files/references_v6.pdf.
6. Schuster H, et al. Effects of switching statins on achievement of lipid goals: Measuring Effective Reductions in Cholesterol Using Rosuvastatin Therapy (MERCURY I) study. Am Heart J., 2004, 147: 705-12.
7. Jones PH, Davidson MH, Stein EA et al. for the STELLAR Study Group. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR Trial). Am J Cardiol, 2003, 92: 152-160.
8. Shalnova SA, Deev AD. Characteristics of patients at high risk. The results of the epidemiological part of the OSCAR Research &Educational Program. Kardiovaskulyarnaya Terapiya i Profilaktika, 2006, 5 (5): 58-63.
9. Fomin E, Baichorov I, Shikh E. Pharmacotherapy of patients with comorbidity: the possibility of drug interactions at the metabolism level. Vrach, 2014, 1: 13-17.
10. Egan A, Colman E.Weighing the benefits of high-dose simvastatin against the risk of myopathy. N Engl J Med, 2011, 365: 285–287.
11. Wiklund O, Pirazzi C, Romeo S. Monitoring of lipids, enzymes, and creatine kinase in patients on lipid-lowering drug therapy. Curr Cardiol Rep, 2013, 15: 397.
12. Mikhin VP, Zhilyaeva YuA, Vorotyntseva VV, Nebieridze DV, Ahmedjanov NM, Vasilyeva DA, Gromnatsky NI. Hypolipidemic and pleotropic efficacy of Rozucard in patients with arterial hypertension and high cardiovascular risk in prolonged outpatient monitoring. Рossiyskiy Kardiologicheskiy Zhurnal, 2016, 12 (140): 90-96.
Review
For citations:
Mikhin VP, Vorotyntseva VV, Zhilyaeva YA, Chernyatina MA, Gromnatsky NI, Sushenya OA. Hypolidemic therapy today. New challenges and opportunities of statines. Meditsinskiy sovet = Medical Council. 2018;(5):48-53. (In Russ.) https://doi.org/10.21518/2079-701X-2018-5-48-53
Views:
909
Email this article 